Exploiting the PI3K/AKT pathway for cancer drug discovery

Bryan T. Hennessy, Debra L. Smith, Prahlad T. Ram, Yiling Lu, Gordon B. Mills

Research output: Contribution to journalReview articlepeer-review

1764 Scopus citations


Evolving studies with several different targeted therapeutic agents are demonstrating that patients with genomic alterations of the target, including amplification, translocation and mutation, are more likely to respond to the therapy. Recent studies indicate that numerous components of the phosphatidylinositol-3-kinase (PI3K)/AKT pathway are targeted by amplification, mutation and translocation more frequently than any other pathway in cancer patients, with resultant activation of the pathway. This warrants exploiting the PI3K/AKT pathway for cancer drug discovery.

Original languageEnglish (US)
Pages (from-to)988-1004
Number of pages17
JournalNature Reviews Drug Discovery
Issue number12
StatePublished - Dec 2005
Externally publishedYes

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery


Dive into the research topics of 'Exploiting the PI3K/AKT pathway for cancer drug discovery'. Together they form a unique fingerprint.

Cite this